In this conference update video, Prof. Valentina Guarneri, Prof. Matteo Lambertini, and Prof. Federico Rojo summarise the key points presented at the highly anticipated EBCC-14 Industry Satellite Symposium and review the current and future treatment landscape for ER+/HER2- advanced breast cancer, with a focus on the metastatic luminal subtype.

 

Topics of discussion include:

  • Overview of the ESMO metastatic breast cancer living guidelines
  • Impact of endocrine resistance and sensitivity
  • The benefit of biomarker-selected endocrine-based therapies in ER+/HER2- advanced breast cancer
  • ESR1 mutation: clinical significance and testing strategies

 

Clinical Takeaways

  • Biomarker-selected endocrine therapies show greater PFS benefits in specific patient subgroups
  • Elacestrant, the first oral SERD to obtain FDA & EMA approval, demonstrates optimal efficacy in ESR1-mutated ER+/HER2- mBC following CDK4/6i treatment
  • Capivasertib, FDA-approved based on the CAPItello-291 study for AKT-pathway altered population, awaits EMA approval as of March 2024
  • ESR1 mutation, holding both prognostic and predictive value, warrants testing upon ET recurrence or progression, using tissue or liquid biopsy

Educational Objectives

  • Conduct a thorough evaluation to determine the underlying causes of HR-positive, HER2-negative breast cancer progression (with a focus on the metastatic luminal subtype)
  • Know the role and be able to implement genomic testing appropriately
  • Implement optimisation of treatment selection, and make the appropriate sequencing decisions in the context of shared decision making

"Valentina Guarneri, MD, PhD, is Full Professor of Oncology at the University of Padua, Head of the Division of Oncology 2 at the Istituto Oncologico Veneto, and head of the Specialization School in medical Oncology at the University of Padova. She completed her fellowship in Oncology in 2003, and she obtained her PhD Degree in Clinical and Experimental Oncology in 2007. In 2005 she was appointed Assistant Professor of Oncology at the University of Modena and Reggio Emilia, where she also chaired the Breast Unit. In 2005, she also completed a 6-month-research experience at the Department of Breast Medical Oncology, UT. MD Anderson Cancer Center, Houston, Texas, where in 2009 she was Visiting Assistant Professor. In 2014 she was appointed Associate Professor of Oncology at the University of Padua.  Prof Guarneri’s research interest is mainly focused on clinical and translational research for breast cancer patients. She has published more than 200 papers in peer-reviewed journals."

Prof. Valentina Guarneri has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Advisory Role: Eisai, Eli Lilly, Exact Sciences, Gilead, Merck Serono, MSD, Novartis, Olema Oncology.

Speakers bureau: Amgen, Eli Lilly, GSK, Gilead, AstraZeneca, Novartis.

Expert testimony: Eli Lilly

Associate Professor and consultant in medical oncology at the University of Genova – IRCCS Policlinico San Martino Hospital in Genova. Member of the guideline group on fertility preservation in cancer patients for ESMO, the European Society of Human Reproduction and Embryology and the Italian Association of Medical Oncology.

Prof. Matteo Lambertini has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Roche, Lilly, Novartis, AstraZeneca, Pfizer, Gilead, MSD, Pierre Fabre, Menarini, Nordic Pharma, Bayer, Ipsen, Daiichi Sankyo, Takeda, Sandoz, Libbs, JCO Consultant Editor, Chair of the ESO Certificate of Competence in Breast Cancer.

Non-financial interests: Member of the executive board of the BIG; Board member of the ISFP; ASCO Annual Meeting Scientific Program Committee on the Breast Cancer – Local/Regional/ Adjuvant Track

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Educational Grant from Menarini Stemline.
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Menarini Stemline.
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
BREAST CANCER CONNECT

BREAST CANCER CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Menarini Stemline Oncology, AstraZeneca and Thermo Fisher Scientific.

Meet the experts Independent IME approved

Other programmes of interest

animated-video Animated Video
Oncology 
The critical role of testing and management in NTRK-positive non-small cell lung cancer (NSCLC)

Using molecular testing to enable personalised care

Experts
Dr Herbert Loong
Endorsed by
ICAN international cancer advocacy network ISLB
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jun 2026
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Bayer.
symposium Masterclass / Symposium
Oncology 
ER+/HER2- metastatic breast cancer: ESMO Breast Cancer 2026 Satellite Symposium highlights

Experts discuss 2nd line+ treatment strategies in endocrine therapy-eligible patients

Experts
Prof. Nadia Harbeck, Dr Tiffany Traina, Prof. Frederik Marmé
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar Jun 2026

This programme has been sponsored by Menarini Stemline and is intended for HCPs only.
conference-update Conference update
Oncology 
Highlights from ASCO 2026

Expert insights on the latest data

Experts
Dr Herbert Loong, Dr Isabel Preeshagul, Prof. Mark Socinski, Prof. Evan Yu, Prof. Hans Prenen, Dr Paolo Tarantino
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Jun 2026
  • Non-accredited Independent Medical Education

Infographic / Flashcard
Oncology Rare diseases 
EP-NEC at a glance

Understanding EP-NEC, emerging treatments, and patient care strategies

Experts
Meredith Cummins
  • download Downloadable
    Resources
  • clock 1 MIN
  • calendar May 2026

This programme has been sponsored by Boehringer Ingelheim
eks
EKS / On-demand webinar
Oncology 
The evolving TROP2-directed ADC landscape in metastatic NSCLC

Strategies to optimise the treatment experience

Experts
Prof. Nicolas Girard, Dr Louise Lim, Dr Jacob Sands, Mrs Stephanie McDonald
Endorsed by
Exon20group Biomarker Collaborative ICAN international cancer advocacy network
  • download Downloadable
    Resources
  • clock 58 MIN
  • calendar May 2026
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from AstraZeneca
conference-update Conference update
Oncology 
Oncogene-addicted NSCLC highlights from ELCC 2026

Expert insights on the latest NSCLC data

Experts
Prof. Nicolas Girard
Endorsed by
ICAN international cancer advocacy network Biomarker Collaborative Exon20group
ISLB Lung Cancer Europe
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Mar 2026
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Bayer.